Lynn Kowalski, MD
Gynecologic Oncology · Las Vegas, NVNPI 1083613616
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,793 of the $15,084 with a category attached, or 91.4%. Integra Lifesciences Corporation accounts for 78.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $11,777, 5.4 times the $2,166 reported in 2019.
Across 86 payments — averaging $175.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$12K
- AstraZeneca$2K
- GSK$464
- Clovis Oncology, Inc.$370
- Intuitive Surgical$145
- Asensus Surgical, Inc.$74
- plus $220 from 7 others
What the payments were for
- Consulting fees$13,79391%
- Food & beverage$1,1978%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 5 | $11,850 |
| AstraZeneca | 2 | $1,962 |
| GSK | 36 | $464 |
| Clovis Oncology, Inc. | 28 | $370 |
| Intuitive Surgical | 4 | $145 |
| Asensus Surgical, Inc. | 1 | $74 |
| Merck | 3 | $64 |
| Seagen Inc. | 1 | $43 |
| Eisai Inc. | 2 | $28 |
| Immunogen, Inc. | 1 | $26 |
| Tesaro, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CODMAN CERTAS$9,575
- CUSA CLARITY$9,575
- OMNIGRAFT$2,275
- INTEGRA$2,275
- LYNPARZA$1,943
- DURASEAL EXACT$125
- CODMAN HAKIM PRECISION VALVE$125
How this compares
Too few gynecologic oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 19 | $278 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Las Vegas
- Alexandra SpirtosLas Vegas$9K
- Natalie GouldLas Vegas$3K
- Nicola SpirtosLas Vegas$2K
- Robert FutoranLas Vegas$1K
- Cheryl BrewerLas Vegas$1K
- Aimee FleuryLas Vegas$1K
- Raymond TurnerLas Vegas$285
- Mary EngelhardtHenderson$2K
- Lauren MontemoranoReno$1K
- Camille FalknerHenderson$71
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.